Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: results from the German hepatitis C cohort (GECCO-01) | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: results from the German hepatitis C cohort (GECCO-01)

Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, et al. Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: results from the German hepatitis C cohort (GECCO-01). Clin Infect Dis. 2016;63(10):1320-1324.

Publication Type:

Journal Article

Authors:

Ingiliz, P.; Christensen, S.; Kimhofer, T.; Hueppe, D.; Lutz, T.; Schewe, K.; Busch, H.; Schmutz, G.; Wehmeyer, MH.; Boesecke, C.; Simon, KG.; Berger, F.; J K Rockstroh; Zur Wiesch, JS.; Baumgarten, A.; Mauss, S.

Source:

Clin Infect Dis., Volume 63, Issue 10, p.1320-1324 (2016)

Notes:

PMID: 27535952

Cited On:

External Third-party Web Link:

https://www.ncbi.nlm.nih.gov/pubmed/27535952

Export Citation:

RIS Format

Top